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Abstract 
Background: Peripheral arterial disease (PAD) is known to be associated with high cardiovascular risk, but the indi-
vidual impact of PAD presentations on risk of macrovascular and microvascular events has not been reliably com-
pared in patients with type 2 diabetes. We aimed to evaluate the impact of major PAD, and its different presentations, 
on the 10-year risk of death, major macrovascular events, and major clinical microvascular events in these patients.
Methods: Participants in the action in diabetes and vascular disease: PreterAx and DiamicroN modified-release con-
trolled evaluation (ADVANCE) trial and the ADVANCE-ON post-trial study were followed for a median of 5.0 (in-trial), 
5.4 (post-trial), and 9.9 (overall) years. Major PAD at baseline was subdivided into lower-extremity chronic ulceration or 
amputation secondary to vascular disease and history of peripheral revascularization by angioplasty or surgery.
Results: Among 11,140 participants, 516 (4.6 %) had major PAD at baseline: 300 (2.7 %) had lower-extremity ulcera-
tion or amputation alone, 190 (1.7 %) had peripheral revascularization alone, and 26 (0.2 %) had both presentations. 
All-cause mortality, major macrovascular events, and major clinical microvascular events occurred in 2265 (20.3 %), 
2166 (19.4 %), and 807 (7.2 %) participants, respectively. Compared to those without PAD, patients with major PAD 
had increased rates of all-cause mortality (HR 1.35, 95 % CI 1.15–1.60, p = 0.0004), and major macrovascular events 
(1.47 [1.23–1.75], p < 0.0001), after multiple adjustments for region of origin, cardiovascular risk factors and treatments, 
peripheral neuropathy markers, and randomized treatments. We have also observed a trend toward an association 
of baseline PAD with risk of major clinical microvascular events [1.31 (0.96–1.78), p = 0.09]. These associations were 
comparable for patients with a lower-extremity ulceration or amputation and for those with a history of peripheral 
revascularization. Furthermore, the risk of retinal photocoagulation or blindness, but not renal events, increased in 
patients with lower-extremity ulceration or amputation [1.53 (1.01–2.30), p = 0.04].
Conclusions: Lower-extremity ulceration or amputation, and peripheral revascularization both increased the risks 
of death and cardiovascular events, but only lower-extremity ulceration or amputation increased the risk of severe 
retinopathy in patients with type 2 diabetes. Screening for major PAD and its management remain crucial for cardio-
vascular prevention in patients with type 2 diabetes (ClinicalTrials.gov number, NCT00949286).
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Background
Peripheral arterial disease (PAD) is a public health prob-
lem across the world with a significant impact on health-
care and a high economic burden [1–5]. It is associated 
with an increased risk of cardiovascular disease [6–8], 
and is particularly common in patients with type 2 dia-
betes [9–12]. Previous studies have shown poor survival 
and cardiovascular outcomes in patients with both type 
2 diabetes and PAD [13–15]. However, the individual 
impact of different presentations of major PAD on sur-
vival and risk of major macrovascular and microvascu-
lar events in patients with type 2 diabetes has not been 
reliably evaluated in long-term prospective studies. The 
Action in Diabetes and Vascular Disease: PreterAx and 
DiamicroN Modified-Release Controlled Evaluation 
(ADVANCE) trial followed patients with type 2 diabetes 
for a median of 5.0 years, and the ADVANCE-ON post-
trial observational study followed them up for further 
5.4 years, to a median overall period of 9.9 years [16, 17]. 
The current investigation aimed to examine the impact of 
major PAD at baseline on the risk of mortality and major 
macrovascular and microvascular outcomes in patients 
with type 2 diabetes across the full 9.9 years, and to com-
pare the effects on these outcomes, of presentation with 
lower-extremity ulceration or amputation on one hand, 
as against presentation with previous peripheral revascu-
larization on the other.
Methods
Population study
ADVANCE was an international randomized trial in 
11,140 patients with type 2 diabetes with the objectives to 
test the effect of intensive glucose control and blood pres-
sure treatment on the incidence of major microvascular 
and macrovacular events [16]. Participants with type 2 
diabetes at high risk of cardiovascular events were ran-
domly assigned to a gliclazide (modified release)–based 
intensive glucose-control regimen, aiming to achieve an 
HbA1c ≤6.5 %, or to standard glucose control, with tar-
gets and regimens based on local guidelines. Participants 
were also randomly assigned to a fixed-dose combina-
tion of perindopril (4 mg) and indapamide (1.25 mg) or 
matching placebo. Subsequently 8494 surviving partici-
pants were enrolled in the post-trial observational evalu-
ation, ADVANCE-ON, study. Design, characteristics of 
participants, and the main results of both studies have 
been previously published [16–19].
Definition of peripheral arterial disease
Major PAD at baseline was defined, as in the ADVANCE 
study, as lower-extremity chronic ulceration (at least 
6  weeks) or amputation below the knee (of at least 
one toe), secondary to vascular disease, or history of 
peripheral revascularization procedure by angioplasty or 
surgery [16]. Two presentations of major PAD were com-
pared: lower-extremity ulceration or amputation versus 
peripheral revascularization. Patients with both presen-
tations (n = 26) were excluded in the comparison of the 
outcomes according to each PAD presentation.
Definition of outcomes
There were three primary outcomes: all-cause mor-
tality, major macrovascular events (a composite of 
nonfatal myocardial infarction, nonfatal stroke, or car-
diovascular death), and major clinical microvascular 
events (a composite of end-stage renal disease (ESRD), 
defined as requirement for renal-replacement therapy; 
death induced by renal disease; requirement for retinal 
photocoagulation; or diabetes-related blindness in either 
eye). The secondary outcomes were cardiovascular death, 
fatal or nonfatal myocardial infarction, fatal or nonfatal 
stroke, ESRD or renal death, and requirement for retinal 
photocoagulation or blindness. Outcomes were adjudi-
cated by an independent End Point Adjudication Com-
mittee in the ADVANCE trial, through to the end of 
randomized treatment, and were reported by investiga-
tors without adjudication in the ADVANCE-ON study, in 
accord with its pre-specified protocol [17]. Information 
about the occurrence of study outcomes and of all serious 
adverse events was reported at the time of occurrence 
between visits. When study outcomes or serious adverse 
events occured, the responsible investigator of each cen-
tre ensured that the event was reported immediately by 
completing a serious adverse events form. The data and 
safety monitoring committee regularly reviewed all such 
events for each centre.
Statistical analyses
Categorical variables were presented as the number of 
patients with the corresponding percentage. Continuous 
variables were expressed as mean (SD) or median (inter-
quartile range) for those with skewed distribution. Char-
acteristics of participants according to major PAD status 
(absence vs. presence) and presentation (lower-extremity 
ulceration or amputation vs. peripheral revasculariza-
tion) were compared at baseline using Chi squared, 
ANOVA, or Wilcoxon tests. Cumulative incidence curves 
were used to plot survival (outcome-free) rates during 
follow-up. Survival curves were compared using the log-
rank test. Cox proportional hazards survival regression 
models were fitted to examine the effect of baseline his-
tory of major PAD and its presentations on time-related 
survival (outcome-free) rates. Hazard ratios (HR), with 
associated 95 % confidence intervals (CI), were estimated 
according to major PAD status at baseline. Basic (model 
1: region of origin, sex, age, body mass index, systolic 
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blood pressure, history of ever smoking and study allo-
cations), and full (model 2: model 1 plus duration of 
diabetes, HbA1c, waist circumference, heart rate, dias-
tolic blood pressure, disturbance of 10-g monofilament 
sensation, absence of ankle and knee reflexes, estimated 
glomerular filtration rate (eGFR) [and its square for mac-
rovascular analyses], total-, and HDL-cholesterol, tri-
glycerides, use of antihypertensive, lipid lowering and 
antiplatelet drugs, and history of current alcohol drink-
ing) adjustments were performed. Participants with a 
history of macrovascular disease (defined as the presence 
at baseline, of myocardial infarction, stroke, coronary 
artery bypass graft, percutaneous transluminal coronary 
angioplasty, hospital admission for unstable angina or 
transient ischaemic attack) were excluded in sensitivity 
analyses. p < 0.05 was considered as significant. Statisti-
cal analyses were performed using SAS software, version 
9.3 (SAS Institute, http://www.sas.com).
Results
Clinical characteristics at baseline
Among 11,140 patients randomized at baseline, 516 
(4.6  %) had a history of major PAD. Clinical character-
istics of participants at baseline are shown in Additional 
file 1: Table S1. Participants with major PAD at baseline, 
compared to those without PAD, were older, and more 
frequently men and from established market economies. 
They had higher body mass index, waist circumference, 
and urinary albumin–creatinine ratio, and lower diastolic 
blood pressure, eGFR, and serum total and HDL-choles-
terol. They were also more likely to use lipid lowering and 
antiplatelet drugs, and to have a history of ever smoking 
or current alcohol drinking. Patients with major PAD had 
also more frequent disturbance of 10-g monofilament 
sensation and absence of ankle and knee reflexes.
Incidence of outcomes during follow‑up according to the 
history of major PAD at baseline
The median (interquartile interval) duration of overall 
follow-up was 9.9 (5.6–10.9) years. All-cause mortal-
ity, major macrovascular events, cardiovascular death, 
and major clinical microvascular events occurred in 
2265 (20.3 %), 2166 (19.4 %), 988 (8.9 %), and 807 (7.2 %) 
participants, respectively. The cumulative incidence of 
all-cause mortality, major macrovascular events, car-
diovascular death, and fatal or non-fatal myocardial 
infarction were higher in participants with history of 
major PAD at baseline compared to those without PAD 
(p  <  0.0001 for all): Fig.  1; Table  1. Significant associa-
tions of PAD with the risk of all-cause mortality (HR 1.35, 
95  % CI 1.15–1.60, p  =  0.0004), major macrovascular 
events (HR 1.47, 95 % CI 1.23–1.75, p < 0.0001), cardio-
vascular death (HR 1.75, 95 % CI 1.39–2.21, p < 0.0001), 
and myocardial infarction (HR 1.58, 95  % CI 1.19–2.09, 
p  =  0.001) persisted after adjustment for all potential 
confounding variables. A trend toward an association of 
major PAD with requirement of retinal photocoagulation 
or blindness persisted in the fully adjusted model (HR 
1.39, 95 % CI 0.99–1.95, p = 0.05). However, we did not 
observe association of major PAD at baseline with the 
risk of ESRD or renal death (Table 1).
Incidence of outcomes during follow‑up according 
to different presentations of major PAD at baseline
Lower-extremity ulceration or amputation, and history 
of peripheral revascularization, not concurrently occur-
ring, were established at baseline in 300 (2.7 %) and 190 
(1.7  %) participants, respectively (p  <  0.0001). Only 26 
(0.2 %) patients had both presentations of major PAD at 
baseline. Compared to those with lower-extremity ulcer-
ation or amputation, participants with history of periph-
eral revascularization, were more frequently men and 
from established market economies (Table 2). They had a 
shorter duration of diabetes, lower eGFR and serum total 
cholesterol, were more likely to use lipid lowering and 
antiplatelet drugs, and to have a history of ever smoking 
or current alcohol drinking. The cumulative incidence 
of all-cause mortality, major macrovascular events, car-
diovascular death, and fatal and non-fatal myocardial 
infarction increased comparably in subjects with dif-
ferent presentations of major PAD, compared to those 
without PAD (Fig. 2; Table 3). Associations of both pres-
entations with all-cause mortality, major macrovascular 
events, cardiovascular death, and myocardial infarction 
were confirmed in the fully adjusted model 2. Further-
more, lower-extremity ulceration or amputation was sig-
nificantly associated with a higher risk of blindness or of 
requirement for retinal photocoagulation (HR 1.53, 95 % 
CI 1.01–2.30, p = 0.04). A non-significant trend toward 
an association of lower-extremity ulceration or ampu-
tation was also observed with the risk of major clini-
cal microvascular events (HR 1.44, 95  % CI 0.98–2.11, 
p  =  0.06). However, no association of lower-extremity 
ulceration or amputation was observed with the risk of 
ESRD or renal death. The risks for outcomes according 
to each presentation of major PAD were comparable for 
mortality and major macrovascular outcomes, but not for 
retinal complications.
Sensitivity analyses
Major PAD was established in 283 (3.7 %) patients among 
7679 participants free from history of macrovascular 
disease at baseline. In this subset of participants, the 
association of major PAD with the risk of all-cause mor-
tality, major macrovascular events and cardiovascular 
death remained significant (Additional file  1: Table S2). 
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Fig. 1 Cumulative incidence of all-cause mortality, major macrovascular events, cardiovascular death, and fatal or nonfatal myocardial infarction 
according to the absence (solid line) or the presence of major PAD (dashed line) at baseline (p < 0.0001 for all)
Table 1 Hazard ratios for outcomes during follow-up by history of major PAD at baseline
Model 1: adjusted for region of origin, sex, age, body mass index, systolic blood pressure, history of ever smoking, and study allocations. Model 2: adjusted as in model 
1 plus duration of diabetes, HbA1c, waist circumference, heart rate, diastolic blood pressure, disturbance of 10-g monofilament sensation, absence of ankle and 
knee reflexes, estimated glomerular filtration rate (and its square for macrovascular analyses), total-, and HDL-cholesterol, triglycerides, use of antihypertensive, lipid 
lowering and antiplatelet drugs, and history of current alcohol drinking. p < 0.05 was significant
Baseline history of major PAD Hazard ratios (major PAD vs. not)
No (n = 10,624) Yes (n = 516) Model 1 Model 2
HR 95 % CI p HR 95 % CI p
All-cause mortality, n (%) 2101 (19.8) 164 (31.8) 1.57 1.33–1.84 <0.0001 1.35 1.15–1.60 0.0004
Major macrovascular events, n (%) 2025 (19.1) 141 (27.3) 1.59 1.34–1.88 <0.0001 1.47 1.23–1.75 <0.0001
Cardiovascular death, n (%) 904 (8.5) 84 (16.3) 1.99 1.59–2.49 <0.0001 1.75 1.39–2.21 <0.0001
Myocardial infarction, n (%) 665 (6.3) 57 (11.0) 1.76 1.34–2.31 <0.0001 1.58 1.19–2.09 0.001
Stroke, n (%) 924 (8.7) 44 (8.5) 1.24 0.92–1.68 0.16 1.19 0.87–1.62 0.28
Major clinical microvascular events, 
n (%)
763 (7.2) 44 (8.5) 1.43 1.05–1.94 0.02 1.31 0.96–1.78 0.09
Retinal photocoagulation or blindness, 
n (%)
632 (5.9) 37 (7.2) 1.48 1.06–2.07 0.02 1.39 0.99–1.95 0.05
End-stage renal disease or renal death, 
n (%)
160 (1.5) 8 (1.6) 1.15 0.56–2.34 0.71 0.96 0.46–1.97 0.90
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Lower-extremity ulceration or amputation, and the his-
tory of peripheral revascularization also remained sig-
nificantly associated with increased risk for all-cause 
mortality (HR 1.60, 95 % CI 1.22–2.10, p = 0.0007, and 
HR 1.57, 95 % CI 1.06–2.34, p = 0.02, respectively) and 
major macrovascular events (HR 1.63, 95 % CI 1.20–2.21, 
p  =  0.002, and HR 1.80, 95  % CI 1.14–2.86, p  =  0.01, 
respectively).
Discussion
We have investigated the risk of vascular outcomes 
with major PAD, and its different presentations, in 
patients with type 2 diabetes followed for 10 years in the 
ADVANCE and ADVANCE-ON studies. Major PAD at 
baseline was associated with increased risk of all-cause 
mortality, major macrovascular events, cardiovascular 
death, and myocardial infarction. Lower-extremity ulcer-
ation or amputation, and the history of peripheral revas-
cularization displayed similar risks of death and major 
cardiovascular events. However, lower-extremity ulcera-
tion or amputation, but not peripheral revascularization, 
was also associated with increased risk of retinal photo-
coagulation or blindness.
History of PAD and risk of macrovascular events
In line with our findings, poor survival and macrovascu-
lar outcomes associated with PAD were reported in other 
prospective studies of patients with type 2 diabetes, even 
Table 2 Clinical characteristics of participants according to different presentations of major PAD at baseline
Comparison of qualitative and quantitative parameters were performed using Chi square and ANOVA tests, respectively. Wilcoxon test was used for variables with 
skewed distribution (duration of diabetes, HbA1c, urinary albumin-creatinine ratio and triglycerides). p < 0.05 was significant
Asia: Philippines, China, Malaysia, India; Established market economies: Australia, Canada, France, Germany, Ireland, Italy, Netherlands, New Zealand, United Kingdom; 
Eastern Europe: the Czech Republic, Estonia, Hungary, Lithuania, Poland, Russia, Slovakia. eGFR, estimated Glomerular Filtration Rate computed by the Chronic Kidney 
Disease Epidemiology Collaboration equation
History of current drinking was defined as consumption of alcohol at least once a week for most weeks of the previous year
Lower‑extremity ulceration  
or amputation (n = 300)
Peripheral revascularization 
(n = 190)
p
Male sex, n (%) 177 (59.0) 140 (73.7) 0.0009
Region of origin: Asia, n (%) 81 (27.0) 12 (6.3) <0.0001
Region of origin: established market economies, n (%) 158 (52.7) 135 (71.0)
Region of origin: Eastern Europe, n (%) 61 (20.3) 43 (22.6)
Age (years): mean (SD) 66.2 (6.7) 66.6 (6.9) 0.55
Duration of diabetes (years): median (Q1, Q3) 8.0 (4.0, 12.0) 6.0 (3.0, 11.0) 0.007
Waist circumference (cm): mean (SD) 101 (14) 102 (14) 0.72
Body mass index (kg/m2): mean (SD) 29.0 (5.9) 28.5 (4.4) 0.32
Heart rate (bpm): mean (SD) 74.5 (11.1) 72.4 (13.2) 0.06
Systolic blood pressure (mmHg): mean (SD) 145 (22) 144 (22) 0.76
Diastolic blood pressure (mmHg): mean (SD) 80 (11) 78 (10) 0.13
Use of antihypertensive treatment, n (%) 210 (70.0) 143 (75.3) 0.21
Disturbance of 10-g monofilament sensation, n (%) 59 (19.7) 30 (15.8) 0.28
Absence of ankle reflex, n (%) 102 (34.0) 51 (26.8) 0.10
Absence of knee reflex, n (%) 54 (18.0) 19 (10.0) 0.02
HbA1c (%): median (Q1, Q3) 7.3 (6.5, 8.7) 7.0 (6.4, 7.9) 0.18
HbA1c (mmol/mol): median (Q1, Q3) 56 (47, 72) 53 (46, 63)
eGFR (ml/min/1.73 m2) 74 (18) 70 (18) 0.01
Urinary albumin to creatinine ratio (µg/mg):  
median (Q1, Q3)
19 (9, 64) 14 (6, 55) 0.06
Serum total cholesterol (mmol/l): mean (SD) 5.2 (1.1) 4.8 (1.0) 0.0004
Serum HDL cholesterol (mmol/l): mean (SD) 1.2 (0.3) 1.2 (0.3) 0.37
Serum triglycerides (mmol/l): median (Q1, Q3) 1.7 (1.2, 2.5) 1.8 (1.2, 2.3) 0.56
Use of lipid lowering drugs, n (%) 103 (34.3) 126 (66.3) <0.0001
Use of antiplatelet drugs, n (%) 139 (46.3) 143 (75.3) <0.0001
History of current smoking, n (%) 47 (15.7) 30 (15.8) 0.97
History of ever smoking, n (%) 153 (51.0) 133 (70.0) <0.0001
History of current drinking, n (%) 86 (28.7) 89 (46.8) <0.0001
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in those who have not been treated with hypoglycae-
mic drugs [13–15, 20]. In the PROspective pioglitAzone 
clinical trial in macrovascular events (PROactive) trial, 
baseline PAD was associated with high risk of all-cause 
mortality, and macrovascular complications in 5238 
patients with type 2 diabetes during a mean follow-up of 
2.9  years [14]. In the Bypass Angioplasty Revasculariza-
tion Investigation 2 Diabetes (BARI 2D) trial, low ankle-
brachial index or non-compressible artery were associated 
with increased risks of death and major cardiovascular 
events in 2368 patients with type 2 diabetes followed for 
an average of 4.3  years [15]. Our larger study demon-
strates that the association of major PAD with death and 
major macrovascular events persisted during 10 years of 
follow-up, even after adjustment for major risk factors. 
Furthermore, these associations persisted in patients free 
for any history of macrovascular disease at baseline.
Presentations of PAD and risk of macrovascular events
As distal PAD is known to be associated with a high rate 
of ulceration and amputation, and is rarely accessible for 
revascularization [9, 21], it is tempting to speculate that 
our patients with history of lower-extremity ulceration 
or amputation, were more likely to have a distal than a 
proximal origin for their PAD. The determination of PAD 
localizations differs among studies, but angiography 
and Doppler ultrasound are still considered as the key 
imaging methods [21, 22]. A recent study has reported 
a semi-quantitative ultrasonographic score to evaluate 
the association of PAD severity and localizations with 
cardiovascular risk factors and adverse events [23]. This 
showed that the magnitude of the association of PAD 
with diabetes was greater with distal than proximal local-
izations. Major PAD presentations had different clinical 
characteristics in our study. Lower-extremity ulceration 
or amputation was more common than peripheral revas-
cularization, and associated with a longer duration of 
diabetes. Furthermore, lower-extremity ulceration, 
amputation, and peripheral revascularization occurred 
concurrently in only 26 patients, suggesting that these 
presentations of major PAD have different origins. Com-
parison of survival, macrovascular and microvascular 
Fig. 2 Cumulative incidence of all-cause mortality, major macrovascular events, cardiovascular death, and fatal or nonfatal myocardial infarction 
according to the absence (solid line) or the presence of lower-extremity ulceration or amputation (dashed line) and peripheral revascularization (dot-
ted line) at baseline (p < 0.0001 for all)
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outcomes according to different presentations of major 
PAD have not been extensively performed in people with 
diabetes. Despite decrease in its prevalence and inci-
dence during last decades in some regions in the world 
[24, 25], lower-extremity amputation will still exert an 
important health burden. Lower-extremity amputation 
and ulceration were associated with increased risk of 
major macrovascular events, and of cardiovascular and 
non-cardiovascular death in patients with diabetes [26–
29]. The risk of major cardiovascular events was also high 
in patients with PAD undergoing peripheral revasculari-
zation in a general population cohort including 39  % of 
participants with diabetes [30]. The pathophysiological 
links by which PAD might predispose to poor vascular 
outcomes have not yet been fully elucidated in patients 
with diabetes. The increased formation of advanced gly-
cation end-products (AGE) and its receptors (RAGE) 
may be a potential pathway linking PAD and other major 
vascular outcomes. A recent study has shown association 
of high plasma levels of AGE-RAGE components with 
increased risk for amputation, PAD, or death in patients 
with type 2 diabetes [31].
Presentations of PAD and risk of microvascular events
Importantly, our findings highlight for the first time, the 
association of lower-extremity ulceration or amputation 
with the risk of severe eye complications during 10-years 
follow-up. This is comparable to a recent cross-sec-
tional study, which showed a higher prevalence of PAD 
in patients with proliferative diabetic retinopathy rather 
than those with non-proliferative retinopathy [32]. We 
have also reported recently, association of history of dia-
betic retinopathy with requirement for laser photocoagu-
lation at baseline with excess risk of major PAD during 
follow-up in ADVANCE study [33]. Our present findings 
are unlikely to be explained by a possible effect of periph-
eral diabetic neuropathy, since associations we have 
observed persisted despite adjustment for disturbance of 
10-g monofilament sensation and absence of ankle and 
knee reflexes. Furthermore, the distribution of the key 
neuropathic markers was comparable between the dif-
ferent presentations of major PAD. However, we did not 
observe an association of either presentation of major 
PAD with the risk of major renal outcomes. Remarkably, 
only 3 patients with major PAD at baseline developed 
ESRD during 10 years of follow-up. Based on their high 
rate of mortality, patients with both PAD and chronic 
kidney disease (CKD) may have died before experiencing 
more advanced renal outcomes [34, 35]. A recent study 
showed that the 4-year mortality rate of patients with 
PAD and CKD stages 4, and 5 was 72 and 78 %, respec-
tively [36].
Strengths and limitations
As compared to previous studies in people with type 2 
diabetes, we have observed a lower prevalence of PAD, 
which may partially be explained by the differences in 
PAD definitions used [13, 14]. The main limitation of our 
investigation is that we have studied patients with symp-
tomatic and severe PAD, and may have underestimated 
outcomes associated with asymptomatic PAD. However, 
our work has several strengths including the investigation 
Table 3 Hazard ratios for outcomes during follow-up according to different presentations of major PAD at baseline
Adjusted as in model 2: region of origin, sex, age, duration of diabetes, body mass index, waist circumference, heart rate, systolic and diastolic blood pressure, 
disturbance of 10-g monofilament sensation, absence of ankle and knee reflexes, HbA1C, estimated glomerular filtration rate (and its square for macrovascular 
analyses), total-, and HDL-cholesterol, triglycerides, history of ever smoking and current alcohol drinking, use of antihypertensive, lipid lowering and antiplatelet 
drugs, and study allocations. p < 0.05 was significant
Absence 
of PAD
Lower‑extremity 
ulceration or 
amputation
Peripheral  
revascularization
Lower‑extremity ulceration 
or amputation
(vs. absent PAD)
Peripheral revasculari‑
zation
(vs. absent PAD)
HR (95 % CI) p HR (95 % CI) p
All-cause mortality, n (%) 2101 (19.8) 92 (30.7) 63 (33.2) 1.39 (1.12-1.72) 0.003 1.31 (1.01–1.70) 0.04
Major macrovascular events, 
n (%)
2025 (19.1) 78 (26.0) 56 (29.5) 1.39 (1.11–1.75) 0.005 1.64 (1.25–2.16) 0.0004
Cardiovascular death, n (%) 904 (8.5) 50 (16.7) 29 (15.3) 1.91 (1.43–2.54) <0.0001 1.52 (1.04–2.23) 0.03
Myocardial infarction, n (%) 665 (6.3) 29 (9.7) 25 (13.2) 1.50 (1.03–2.19) 0.03 1.73 (1.14–2.62) 0.01
Stroke, n (%) 924 (8.7) 24 (8.0) 18 (9.5) 1.02 (0.67–1.55) 0.92 1.54 (0.96–2.48) 0.07
Major clinical  
microvascular events, n (%)
763 (7.2) 28 (9.3) 11 (5.8) 1.44 (0.98–2.11) 0.06 0.88 (0.48–1.61) 0.68
Retinal photocoagulation or 
blindness, n (%)
632 (5.9) 24 (8.0) 9 (4.7) 1.53 (1.01–2.30) 0.04 0.94 (0.48–1.83) 0.85
End-stage renal disease or 
renal death, n (%)
160 (1.5) 4 (1.3) 3 (1.6) 0.84 (0.31–2.30) 0.74 0.94 (0.29–3.02) 0.92
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of a large contemporary cohort of patients with type 2 
diabetes at high cardiovascular risk, with a comprehen-
sive clinical history of major PAD at baseline, and pre-
specified major endpoints during the study period.
Conclusions
Our study underlines worse survival and cardiovascular 
outcomes in patients with type 2 diabetes and major PAD 
during 10 years of follow-up. Lower-extremity ulceration 
or amputation, and peripheral revascularization had sim-
ilar effects on the risk of these outcomes. Furthermore, 
lower-extremity ulceration or amputation was associ-
ated with higher incidence of severe eye disease. Prompt 
screening and more intensive management of both pres-
entations of major PAD may help to improve prognosis, 
particularly cardiovascular outcomes in patients with 
long-standing type 2 diabetes.
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